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Background: Cervical cancer cells often express Epidermal Growth Factor Receptor 
(EGFR). Cetuximab (CET), an anti-EGFR monoclonal antibody, can be safely combined 
with carboplatin (C) and paclitaxel (P), a standard treatment of advanced or recurrent 
cervical cancer (ARCC) patients (pts). This is a comparative randomized phase 2 study, 
testing the addition of CET to CP.  
Methods: ARCC pts, <2 previous chemotherapy, ECOG PS≤1, were randomized to CP (C 
AUC5 + P 175 mg/m², d1q21) for 6 cycles +/- CET (400 mg/m² one week before starting 
CP, then 250 mg/m² weekly) until disease progression or unacceptable toxicity. Primary 
endpoint was event-free survival (EFS), i.e. time from randomization to progression, death, 
definitive discontinuation of the whole treatment or loss to follow-up, whichever occurred 
first. With a 4.5 months (mos) expected median EFS and a 6.4 mos predicted EFS (HR 
0.70), 0.20 one-tailed α and 80% power, 89 events were required for the final intent-to-
treat analysis.  
Results: 108 pts were randomly assigned to CP (n=53) or to CP-CET (n=55). A patient in 
CP arm withdrew the consent and was not analyzed. Median age was 50, 69% were PS 0, 
76% had recurrent disease, 91% had distant metastasis and 57% had received previous 
chemotherapy. After a median follow-up of 23 mos, 102 pts had an event, 97 progressed 
and 61 died. Median EFS was 4.7 and 6.0 mos (one-tail p=0.43), median progression free 
survival (PFS) was 5.2 and 7.6 mos (one-tail p=0.20) and median Overall Survival (OS) 
was 17.7 and 17 mos (one-tail p=0.27), with CP and CP-CET, respectively. There was no 
difference in the occurrence of severe adverse events, except for skin toxicity.  
Conclusion: The addition of CET to CP was feasible but not more active than CP alone in 








Cervical cancer is the fourth most common female cancer worldwide and has the fourth 
highest cancer-related mortality rate in women, with estimates of 528.000 new cases and 
266.000 deaths from the disease per year 1. Effective screening and prevention programs 
in developed countries have resulted in a 75% decrease in the incidence and mortality of 
cervical cancer over the past 50 years 2. However, in developing countries, cervical cancer 
accounts for almost 12% of all cancers in females and remains the most common cancer 
in women in eastern and central Africa.   
Surgery and chemo-radiotherapy have a high curative rate in early-stage cervical cancer. 
However, patients with recurrent or metastatic cancer have limited therapeutic options. 
The poor long-term results of standard treatment for cervical cancer compel research into 
new, more beneficial treatment strategies 3. Cervical cancer cells express the Epidermal 
Growth Factor Receptor (EGFR) in a very high proportion of cases with increasing levels 
from intraepithelial disease to invasive carcinoma 4,5. Expression is present also in 
metastatic or recurrent cancer more than in localized tumours. High level of expression of 
EGFR has been correlated with poor prognosis 6,7, despite some contradictory results. 
Cetuximab, an anti-EGFR monoclonal antibody, has shown efficacy in several epithelial 
tumor types. In particular, the combination of cetuximab and chemotherapy prolonged 
survival outcomes as compared with chemotherapy alone, in advanced colorectal 8-10 and 
head and neck cancer 11.  
In preclinical studies, Cetuximab significantly inhibited tumor proliferation in cervical tumor 




From previous experiences, cetuximab can be safely combined with full-dose carboplatin 
and paclitaxel 12, which is a standard option for treatment of advanced or recurrent cervical 
cancer patients 13-16.  
The possibility of combining cetuximab with full doses of carboplatin and paclitaxel 
prompted us to evaluate the activity of the addition of cetuximab to carboplatin and 






PATIENTS AND METHODS 
 
Study design 
This was a phase II, prospective, open-label, randomized (1:1), multicenter clinical trial, 
comparing two treatment arms: Carboplatin + Paclitaxel versus Carboplatin + Paclitaxel+ 
Cetuximab.  
Event-free survival (EFS) was the primary end-point, defined as the time from 
randomisation to progression, death without progression, premature definitive 
discontinuation of the whole treatment or loss to follow up, whichever occurred first.  
Because of the exploratory nature of the study, a so-called relaxed statistical design was 
chosen for comparison: one-tailed test, significance level equal to 20%, power equal to 
80% 17,18. Assuming a median EFS in the control arm equal to 4.5 months and a median 
EFS in the experimental arm equal to 6.4 months (corresponding to a Hazard ratio of 
0.70), 89 events were required and 108 patients (54 for each arm) were planned (EAST 5 
software, Cytel Software, Cambridge, MA, U.S.A.).  
Secondary endpoints included progression-free survival (PFS), overall survival (OS), 
toxicity and objective response rate (ORR). Patient registration and data collection were 
performed through dedicated electronic CRFs available on the website of the Clinical 
Trials Unit, National Cancer Institute, Napoli, Italy (http:\\www.usc-intnapoli.net). 
Randomisation was performed centrally,  through the above reported website, by a 
computer-driven minimization procedure. The number of previous chemotherapy (none vs 
one), the presence of distant metastases (no vs yes) and the centre, were considered as 
stratification variables. No blinding procedure was planned.  
This study was available in public registries (ClinicalTrials.gov ID: NCT00997009 and 





Women with advanced or metastatic cervical cancer, untreated or having failed only one 
previous chemotherapy (with or without concomitant or sequential radiotherapy and with at 
least 6 months of progression-free interval), not amenable for surgery or radiotherapy, with 
at least one measurable lesion by the Response Evaluation Criteria In Solid Tumours 
(RECIST), an ECOG performance status 1, and a life expectancy 3 months were 
eligible. Adequate hematopoietic (absolute neutrophils count ≥1,500/mm3; platelets count 
≥100,000/mm3; hemoglobin ≥9 g/dL), hepatic (SGOT or SGPT≤3 UNL or ≤5 ULN in 
presence of liver metastases, alkaline phosphatase ≤3 ULN, total bilirubin ≤1.5 UNL), and 
renal (calculated creatinine clearance ≥ 45 mL/min) function were required. 
Exclusion criteria were: a history of heart failure, angina pectoris, myocardial infarction 
(within 1 year from study entry), uncontrolled hypertension or arrhythmia; active infection 
requiring antibiotics; previous invasive malignancy within the past 5 years except non-
melanoma skin cancer; residual peripheral neuropathy >grade 2 according to Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0; concurrent treatment with 
other experimental drugs; pregnancy and breast-feeding. The study was approved by 
Ethics Committees at each participating Institution, and all the patients signed the informed 
consent before any study related procedure. 
 
Study treatment  
Patients were randomly assigned, with a 1:1 ratio, to receive either carboplatin and 
paclitaxel (standard arm) or carboplatin and paclitaxel plus cetuximab (experimental arm). 
Patients in both arms received paclitaxel 175 mg/m² (diluted in 250 ml of 0.9% saline and 




and infused intravenously over 30 minutes) on day one every 21 days, for a maximum of 6 
cycles. 
Patients in the experimental arm received cetuximab intravenous infusion, at a starting 
dose of 400 mg/m2 over 120 minutes, one week before starting chemotherapy, and further 
weekly infusion at the dose of 250 mg/m2 over 60 minutes, until disease progression, 
prolonged/unacceptable toxicity or patient’s withdrawal. 
In the experimental arm, a prophylactic premedication with dexamethasone 8 mg 
intravenously and antihistamine (such as diphenhydramine 50 mg) intravenously was 
mandatory before the first administration of cetuximab and also strongly recommended 
before the following weekly doses. In both arms, a prophylactic premedication with 
dexamethasone 20 mg (or hydrocortisone 250 mg), chlorpheniramine 10 and ranitidine 50 
mg intravenously was given before paclitaxel infusion.  
In both arms, chemotherapy had to be deferred if absolute neutrophils count 1,500/mm3, 
platelets count 100,000/mm3, or organ toxicity grade ≥2 (excluding alopecia and skin 
toxicity), for up to two consecutive weeks, until recovery. In case of a delay of more than 2 
weeks, chemotherapy had to be discontinued. Chemotherapy dose had to be reduced by 
20% in case of neutrophils <500/mm3 for a period of more than 7 days or platelets 
<50000/mm3. In case of grade 2 neurotoxicity paclitaxel dose had to be reduced by 20%, 
while it had to be definitively stopped in case of grade ≥3 neurotoxicty. In case of 
chemotherapy delay or stop, cetuximab could continue as planned. 
Cetuximab had to be delayed in case of grade ≥3 (according to CTCAE version 3.0) skin 
toxicities, for up to two consecutive infusions, until toxicity resolved to grade 2. Cetuximab 
dose did not change after the first delay, while it had to be reduced to 200 mg/m2 and 150 
mg/m2 after the second and third occurrence of a grade ≥3 skin toxicity, respectively. Dose 




consecutive infusions were withheld or on the fourth occurrence of a grade ≥3 skin toxicity 
despite appropriate dose reduction. Cetuximab infusion rate had to be decreased by 50% 
after the first occurrence of grade 2 allergic/hypersensitivity reaction, while it had to be 
definitively stopped in case of grade ≥3 allergic/hypersensitivity reaction or on the second 
occurrence of a grade 2 allergic/hypersensitivity reaction despite appropriate infusion rate 
reduction. In case of cetuximab delay or stop, chemotherapy could continue as planned. 
 
Patient evaluation 
Disease assessment included clinical examination, abdomino-pelvic CT scan and chest X-
ray, and were performed at baseline and repeated every 3 cycles during chemotherapy 
and every 3 months thereafter. Objective response was codified according to RECIST 19. 
Safety assessment included physical examination, blood tests (haematology and 
biochemistry) and collection of adverse events history, which were performed at least 
every 3 weeks during treatment and until 30 days after the last administration of study 
drugs. Moreover an ECG was performed every three cycles during chemotherapy. 
Adverse events were coded according to CTCAE version 3.0. Skin toxicity was also 
graded according to the MASCC (Multinational Association of Supportive Care in Cancer) 
EGFR inhibitor skin toxicity tool (MESTT©) 20. 
 
Statistical analysis 
All the efficacy analyses were done on an intention-to-treat basis. EFS was defined as the 
time from randomization to progression, death without progression, premature definitive 
discontinuation of the whole treatment or loss to follow-up, whichever occurred first. 
Patients who discontinued the treatment due to symptomatic deterioration in absence of 




deterioration. The whole treatment was considered as prematurely discontinued if all the 
planned drugs were definitively suspended for reasons different from progression or 
completion of the planned treatment. A patient was considered as lost to follow-up if at the 
date of the database lock for the primary analysis she missed the last two consecutive 
follow-up visits. Patients who did not have an event according to the above definition were 
censored at the last visit, when the patient was known to be alive and free from 
progression. 
PFS was defined as the time from randomization to progression or death (whichever 
occurred first) or date of last visit when the patient was known to be alive and free from 
progression. OS was defined as the time from randomisation to death or date of last 
follow-up for patients alive. Median follow-up (mFU) was calculated according to the 
reverse Kaplan-Meier technique 21. EFS, PFS and OS curves were estimated by Kaplan-
Meier product limit method 22 and compared by log-rank test.  
ORR was defined as the proportion of complete plus partial responder among patients with 
at least one target lesion according RECIST. Patients eligible for the evaluation of the 
response who did not perform the restaging were classified as “not evaluated” and 
conservatively included among the non-responders. Independent review of radiologic tests 
was not performed and no formal rules regarding blinding of local radiologists were 
implemented into the protocol. ORRs between the treatment arms were compared by chi-
square test.  
 
All subjects who received at least one dose of study treatment were included in 
compliance and safety analyses. For each toxicity and each patient, the worst degree ever 
suffered during treatment was used for the analysis. The whole pattern of toxicity (all 




Wallis linear rank test. Statistical analyses were performed using S-Plus version 6.1 
(Insightful Corp., Seattle, WA, U.S.A.). Exact tests were performed using Cytel Studio 10 








Between February 3, 2010 and May 8, 2013, 108 patients were randomly assigned to 
standard (n=53) or experimental (n=55) arm (Figure 1). One patient was excluded from 
analysis because she withdrew consent immediately after randomisation. Therefore, the 
survival analyses included 107 patients (Figure 1). Baseline characteristics of the patients 
were balanced between the arms (Table 1).  All 107 patients received at least one dose of 
the assigned treatment (no case of treatment violation) and, therefore, were included in 
the compliance and safety analyses.  
 
Treatment compliance 
Median number of chemotherapy cycles was 6 (IQR 4-6) in the both arms. Median relative 
dose intensity (RDI) for carboplatin was 92% (IQR 86%-100%) and 91% (IQR 85%-98%) 
in the control and experimental arm, respectively. Median RDI for paclitaxel was 90% (IQR 
80%-98%) and 89% (IQR 80%-94%) in the control and experimental arm, respectively. 
Median RDI for cetuximab was 82% (IQR 76%-90%). At least one dose reduction was 
applied to chemotherapy in 17 (33%) and 21 (38%) patients in the control and 
experimental arm, respectively.  Cetuximab dose was reduced in 4 patients (7%). Overall, 
35 (67%) and 34 (62%) patients completed the planned chemotherapy. Chemotherapy 
was discontinued due to reasons other than completion or progression/death in 3 (6%)  
and 7 (13%) patients in the control and experimental arm, respectively. Cetuximab was 
discontinued due to toxicity or refusal by 13 patients (24%); one patient was still on 






With data locked on March 15, 2015, after a median follow-up of 23 months (95% CI: 20-
26), 102 patients had an event for the primary analysis (48 and 54 in the standard and 
experimental arm, respectively). The event was progressive disease for 83 patients, death 
without evidence of progression for 2 patients, definitive stop of the treatment for 15 
patients and loss to follow-up for 2 patients. Overall, 97 patients progressed (45 and 52 
progressions in the standard and experimental arm, respectively) and 61 died (30 and 31 
death in the standard and experimental arm, respectively). 
Median EFS was 4.7 with the standard treatment and 6.0 months with the experimental 
treatment and the difference was not statistically significant (HR 0.97, 95% CI: 0.66-1.43; 
one-tailed log-rank test p=0.43). Median PFS was 5.2 and 7.6 months (HR 0.84, 95% CI: 
0.56-1.26; one-tailed log-rank test p=0.20) and median OS was 17.7 and 17 months (HR 
0.85, 95% CI: 0.52-1.42; one-tailed log-rank test p=0.27), with standard and experimental 
treatment, respectively (Figures 2-4).   
Twenty-one patients (8 in the control arm and 13 in the standard arm) were found ineligible 
after randomisation, as they did not have measurable disease according to RECIST at 
baseline assessment. Therefore, 86 (80.4%) patients were eligible for response analysis 
according to RECIST 1.0, 44 (84.6%) and 42 (76.4%) in the control and experimental arm, 
respectively. Nineteen patients (43%, 95% CI: 30%-58%) in the standard arm and 16 
patients (38%, 95% CI: 25%-53%) in the experimental arm achieved an objective 
response (Chi square p=0.79) (Table 3).  
 
Safety analysis 
The worst per patient toxicity according to CTCAE 4.0 distributed per treatment arm, is 




stroke during standard treatment. There was no difference between treatment arms in the 
occurrence of adverse events, except, as expected, for diarrhoea (only not severe) and 
skin toxicity. 
Overall, at least one severe (grade ≥3) adverse event was reported in 30 (58%) patients in 
the control arm and 44 (80%) in the experimental one. As expected, severe skin toxicity 
was reported only in the experimental arm (9 patients reported a grade 3 skin toxicity, 6 of 
whom had acneiform skin rash). 
Skin toxicity reported according to the MASCC EGFR inhibitor Skin Toxicity Tool (MESTT) 
is summarized in Table 5. Twelve patients reported a severe (all grade 3) toxicity with 






The addition of cetuximab to carboplatin and paclitaxel in the treatment of patients with 
advanced or recurrent cervical cancer, did not improve EFS (primary end-point), PFS, OS 
nor ORR in the MITO CERV-2 trial. 
Other three unsuccessful phase 2 trials of cetuximab in advanced cervical cancer were 
conducted during the same years. A single-arm GOG trial of single agent cetuximab in 35 
pretreated patients failed to show any activity, with no objective response reported and an 
unsatisfactory PFS rate at 6 month 23. A GINECO trial tested the activity of the 
combination of cetuximab with cisplatin and topotecan as first-line chemotherapy for 
advanced disease 24. This was a single-arm trial with ORR as primary end-point but was 
stopped early, with 19 enrolled out of 44 planned patients, for an unexpected excess of 
severe and fatal toxicity (infections and myelotoxicity). Another GOG study, enrolling 76 
patients, tested the combination of cetuximab with cisplatin only as first line treatment for 
advanced recurrent or persistent disease. The combination was well tolerated but not 
active as predicted. In this study, the investigator collected baseline tumor specimens and 
found a correlation between a high tumoral EGFR expression and advanced stage and 
shorter PFS 25.  
Our study tested the addition of cetuximab to a doublet chemotherapy scheme including 
carboplatin and paclitaxel, a combination that has been largely evaluated in lung cancer 
treatment, and that was therefore considered safe. Indeed, we had no problem of 
tolerability and the addition of cetuximab increased skin toxicity only.  
We chose a randomised comparative design with statistical criteria that, accepting a high 
alpha error, allow an adequate power to screen a promising treatment, to be evaluated for 




as expected, with a median EFS of 4.7 months found and a median EFS of 4.5 months 
anticipated under the null hypothesis. We chose a composite endpoint, EFS, as primary 
end-point since it includes as event the discontinuation of treatment due to causes 
different from progression, such as toxicity or patient choice, and it could be relevant for a 
treatment that is scheduled until progression of disease and has a specific, socially 
relevant, toxicity. However, the addition of cetuximab did not substantially improve also the 
secondary outcomes. 
 
Our study enrolled molecularly unselected patients, while it is known that mutations of 
RAS, an EGFR downstream signalling molecule, are strongly predictive of lack of efficacy 
of cetuximab in colorectal cancer. In SCCHN patients, RAS mutations, rare at baseline, 
seem to be involved in the acquired resistance to cetuximab treatment 26. However, 
neither  RAS or EGFR mutations, nor EGFR gene amplification, were associated with 
benefit from cetuximab in lung cancer 27, whilst contrasting results were reported for high 
EGFR protein expression as positive predictive factor 27,28.  
We cannot exclude that there might exist cervical cancer molecular subgroups that could 
be sensitive or resistant to cetuximab treatment. We tried to retrospectively collect tumor 
samples for an exploratory biomarker analysis, with the aim of identifying molecular 
alterations predictive of cetuximab clinical activity and, possibly, to optimize its use; but 
unfortunately, only a very low number of samples were retrieved and we cannot conduct 
any explorative subgroup analysis. 
In previous studies, EGFR was showed to be overexpressed in most of cervical cancers 5 
and RAS mutations seemed to be rare or even absent in cervical carcinoma 29. Therefore, 
in principle, cetuximab would be active in this tumor. Recently, within a randomised study 




a molecular analysis of baseline tumor samples found that no tumor had an EGFR 
mutation, 4% of tumors only had a KRAS mutation while 22% had a PIK3CA mutation 30. A 
complete response was observed in 27% of patients without PIK3CA mutations but in 
none of the patient with one or more PIK3CA mutations, suggesting a correlation between 
these mutations and cetuximab resistance.  
In conclusion, our trial showed that the addition of cetuximab to carboplatin and paclitaxel 
was feasible but not more effective than chemotherapy alone and does not deserve phase 
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Table 1 : Baseline characteristics 
 Carboplatin/Paclitaxel  
 
(n =52)  
Carboplatin/Paclitaxel 
+ Cetuximab  
(n=55)  
Median age (IQR)  52 (44-62) 47 (41-60) 
Previous chemotherapy    
     No  22 (42%) 24 (44%) 
Yes  30 (58%) 31 (56%) 
Distant metastasis    
     No  9 (17%) 10 (18%) 
Yes  43 (83%) 45 (81%) 
ECOG performance status    
     0  33 (64%) 40 (73%) 
     1  19 (36%) 15 (27%) 
Histotype    
Adenocarcinoma  11 (21%) 12 (22%) 
Squamous  41 (79%) 43(78%) 
Grade   
1 1 (2%) 1 (2%) 
2 8 (15%) 20 (36%) 
3 31 (60%) 27 (49%) 






Table 2. Treatment compliance  
 Carboplatin/Paclitaxel  
 




Chemotherapy   
No. of cycles, median (IQR) 6 (4-6) 6 (4-6) 
No. of patients   
At least one delay 17 (33%) 21 (38%) 
At least one dose reduction 12 (23%) 8 (14%) 
Cause of treatment interruption   
 Completion    35 (67%) 34 (62%) 
 Progression or death    14 (27%) 14 (25%) 
 Toxicity or refusal    2 (4%) 7 (13%) 
 Medical decision    1 (2%) 0 (0%) 
Cetuximab   
No. of weeks, median (IQR) - 26 (14-35) 
Number of patients   
At least one delay - 27 (49%) 
At least one dose reduction - 4 (7%) 
Cause of treatment interruption   
 Progression or death - 41 (74%) 
 Toxicity or refusal - 13 (24%) 
 Still on treatment - 1 (2%) 







Table 3. Objective response according to treatment arm 
 Carboplatin/Paclitaxel  
 



















PR 14 (32%) 14 (33%)  
Non responders 25 (57%) 26 (62%)  
 SD 8 (18%) 14 (33%)  
 P 11 (25%) 6 (14%)  
 Not evaluated 6*(14%) 6** (14%)  
CR: complete response; PR: partial response; SD: stable disease; P: progression. 
* 4 patients underwent, at the restaging, a radiologic exam different than the baseline one; 2 patients did not undergo 
restaging owing to early clinically assessed PD. 
** 2 patients underwent,  at the restaging, a radiologic exam different than the baseline one; 4 patients did not undergo 






Table 4. Worst per patient toxicity comparison  
*P value from the Kruskal Wallis exact test 
 























n (%) n (%) n (%) n (%) n (%) 
 
n (%) n (%) n (%) n (%) n (%) P* 
Anemia 14 (27) 14 (27) 7 (13) 1 (2) 0 (0) 
 
13 (24) 14 (25) 8 (15) 0 (0) 0 (0) 0,68 
Leucopenia 4 (8) 15 (29) 12 (23) 0 (0) 0 (0) 
 
5 (9) 9 (16) 10 (18 5 (9) 0 (0) 0,85 
Neutropenia 2 (4) 10 (19) 12 (23) 8 (15) 0 (0) 
 
3 (5) 6 (11) 15 (27) 11 (20) 0 (0) 0,55 
Febrile Neutropenia 0 (0) 0 (0) 0 (0) 2 (4) 0 (0) 
 
0 (0) 0 (0) 3 (5) 3 (5) 0 (0) 0,27 
Infection 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 
 
0 (0) 2 (4) 1 (2) 0 (0) 0 (0) 0,55 
Thrombocytopenia 6 (12) 6 (12) 3 (6) 1 (2) 0 (0) 
 
4 (7) 7 (13) 5 (9) 1 (2) 0 (0) 0,86 
Hemorrage 4 (8) 1 (2) 2 (4) 0 (0) 0 (0) 
 
2 (4) 3 (5) 0 (0) 0 (0) 0 (0) 0,46 
Allergy 0 (0) 1 (2) 1 (2) 0 (0) 0 (0) 
 
1 (2) 1 (2) 1 (2) 1 (2) 0 (0) 0,60 
Heart, rhythm 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 
 
2 (4) 1 (2) 0 (0) 0 (0) 0 (0) 0,55 
Heart, general  2 (4) 3 (6) 0 (0) 0 (0) 0 (0) 
 
4 (7) 1 (2) 0 (0) 0 (0) 0 (0) 0,81 
Thrombosis/embolism 0 (0) 1 (2) 1 (2) 0 (0) 0 (0) 
 
0 (0) 0 (0) 1 (2) 3 (5) 0 (0) 0,46 
Fever 3 (6) 1 (2) 0 (0) 0 (0) 0 (0) 
 
6 (11) 4 (7) 1 (2) 0 (0) 0 (0) 0,07 
Fatigue 14 (27) 9 (17) 3 (6) 0 (0) 0 (0) 
 
18 (33) 9 (16) 6 (11) 0 (0) 0 (0) 0,31 
Constitutional, other 2 (4) 1 (2) 0 (0) 0 (0) 0 (0) 
 
3 (5) 1 (2) 2 (4) 0 (0) 0 (0) 0,38 
Hair loss 0 (0) 16 (31) 0 (0) 0 (0) 0 (0) 
 
8 (15) 15 (27) 0 (0) 0 (0) 0 (0) 0,53 
Anorexia 5 (10) 0 (0) 0 (0) 0 (0) 0 (0) 
 
2 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0,26 
Constipation 11 (21) 7 (13) 1 (2) 0 (0) 0 (0) 
 
5 (9) 7 (13) 0 (0) 1 (2) 0 (0) 0,22 
Diarrhoea 1 (2) 3 (6) 0 (0) 0 (0) 0 (0) 
 
9 (16) 4 (7) 1 (2) 0 (0) 0 (0) 0,02 
Mucositis 2 (4) 2 (4) 0 (0) 0 (0) 0 (0) 
 
4 (7) 3 (5) 3 (5) 0 (0) 0 (0) 0,11 
Nausea 13 (25) 6 (12) 0 (0) 0 (0) 0 (0) 
 
10 (18 7 (13) 0 (0) 0 (0) 0 (0) 0,65 
Vomiting 6 (12) 9 (17) 0 (0) 0 (0) 0 (0) 
 
9 (16) 2 (4) 0 (0) 0 (0) 0 (0) 0,18 
Liver 4 (8) 1 (2) 0 (0) 0 (0) 0 (0) 
 
6 (11) 1 (2) 0 (0) 0 (0) 0 (0) 0,73 
Renal/Genitourinary 4 (8) 2 (4) 1 (2) 0 (0) 0 (0) 
 
4 (7) 2 (4) 2 (4) 0 (0) 0 (0) 0,88 
CNS ischemia 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 
 
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1,00 
Sensory neuropathy  15 (29) 5 (10) 0 (0) 0 (0) 0 (0) 
 
12 (22) 7 (13) 1 (2) 0 (0) 0 (0) 1,00 
Neurology other 3 (6) 3 (6) 1 (2) 0 (0) 0 (0) 
 
3 (5) 2 (4) 0 (0) 0 (0) 0 (0) 0,43 
Pain 1 (2) 2 (4) 1 (2) 1 (2) 0 (0) 
 
1 (2) 2 (4) 3 (5) 0 (0) 0 (0) 0,89 
Pulmonary 1 (2) 1 (2) 1 (2) 0 (0) 0 (0) 
 
3 (5) 0 (0) 0 (0) 0 (0) 0 (0) 0,74 
Dry skin 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 
 
5 (9) 2 (4) 1 (2) 0 (0) 0 (0) 0,03 
Flushing 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 
6 (11) 3 (5) 0 (0) 0 (0) 0 (0) 0,003 
Nail changes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 
3 (5) 4 (7) 1 (2) 0 (0) 0 (0) 0,006 
Pruritus  1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 
 
6 (11) 1 (2) 0 (0) 0 (0) 0 (0) 0,06 
Rash/desquamation 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 
 
5 (9) 10 (18) 1 (2) 0 (0) 0 (0) 0,0520 
Rash/acneiform 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 
 
13 (24) 14 (25) 6 (11) 0 (0) 0 (0) <0,0001 
Skin, other 1 (2) 1 (2) 0 (0) 0 (0) 0 (0) 
 




Table 5. Worst per patient skin toxicity according to MASCC EGFR inhibitor skin toxicity 




Carboplatin/Paclitaxel + Cetuximab 
Grade 1 2 3 4 
 
1 2 3 4 
 
A B A B A B 
  
A B A B A B 
 
 
n (%) n (%) n (%) n (%) n (%) n (%) 
  
n (%) n (%) n (%) n (%) n (%) n (%) 
 
Papulopustular eruption 0 0 0 0 0 0 _ 
 
11 (20) 3 (5) 7 (13) 1 (2) 2 (4) 5 (9) _ 
Nail Changes-Nail Plate 0 0 0 0 _ 
 
3 (5) 1 (2) 0 0 _ 
Nail Changes-Nail Fold 0 0 0 _ 
 
0 2 (4) 0 _ 
Nail Changes-Digit tip 0 0 0 _ 
 
1 (2) 2 (4) 1 (2) _ 
Erythema 1 (2) 0 0 _ 
 
18 (33) 8 (15) 2 (4) _ 
Pruritus 1 (2) 0 0 0 _ 
 
4 (7) 0 0 0 _ 
Xerosis 1 (2) 0 0 0 0 _ 
 
11 (20) 0 0 0 0 _ 
Hair changes-Alopecia 0 14 (27) 2 (4) _ _ _ 
 
8 (15) 12 (22) 3 (5) _ _ _ 
Hair changes-Increased hair  0 0 0 _ _ _ 
 
0 3 (5) 1 (2) _ _ _ 
Flushing 0 0 0 0 0 0 _ 
 
4 (7) 2 (4) 1 (2) 1 (2) 1 (2) 0 _ 
Hyperpigmentation 0 0 0 0 _ 
 
2 (4) 0 0 0 _ 
Mucositis 3 (6) 0 0 0 
 
3 (5) 3 (5) 3 (5) 0 
Taste 0 0 0 _ 
 










Figure 1.  
Study flow.  
Figure 2.  
Event-free survival (EFS) curves by treatment arm.  
Figure 3.  
Progression-free survival (PFS) curves by treatment arm.  
Figure 4.  







List of MITO CERV-2 participating Institutions (town), physicians, research nurses 
and data managers. 
1. Dipartimento di Oncologia Uroginecologica, Istituto Nazionale per lo Studio e la Cura 
dei Tumori  "Fondazione G.Pascale" IRCCS (Napoli): Sandro Pignata, Carmela 
Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Stefano Greggi, Rosa Tambaro, 
Laura Arenare, Angela Maria Trujillo, Margherita Tambaro. 
2.  Dipartimento per la Tutela della Salute della Donna della Vita Nascente del Bambino e 
dell' Adolescente, Fondazione Policlinico Universitario Gemelli, Università Cattolica del 
Sacro Cuore (Roma): Giovanni Scambia, Gabriella Ferrandina, Vanda Salutari, Giulia 
Amadio, Mariagrazia Distefano, Rosa Pasqualina De Vincenzo, Caterina Ricci, 
Antonella Pietragalla, Alessia Di Legge, Michela Panella. 
3. Unità di Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale Tumori 
(Milano): Domenica Lorusso, Francesco Raspagliesi, Giuseppa Maltese, Stefano 
Lepori, Antonino Ditto, Giorgio Bogani, Ilaria Sabatucci, Valentina Chiappa, Cono 
Scaffa, Mauro Signorelli, Elisa Grassi. 
4. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori – IRCSS (Meldola-
Cesena): Ugo De Giorgi, Barbara Kopf, Salvatore Luca Burgio, Cecilia Menna, 
Vincenza Conteduca, Valentina Gallà. 
5. Istituto Oncologico Veneto IRCCS (Padova): Maria Ornella Nicoletto, Alessandra 
Baldoni, Simona Frezzini, Giulietta Sinigallia. 
6. Università Federico II (Napoli): Rossella Lauria, Cinzia Cardalesi. 
7. Oncologia Medica, Ospedale S. Maria della Misericordia (Perugia): Annamaria 
Mosconi, Tella Porrozzi, Fabiana Marchetti. 
8. Ospedale Universitario "S. Maria della Misericordia” (Udine): Cosimo Sacco, Claudia 
Andretta, Roberta Sottile. 
9. Oncologia Medica, Azienda Ospedaliero Universitaria Policlinico (Modena): Roberto 
Sabbatini, Elisabetta Filieri, Pasquale Mighali. 
10. Oncologia Medica, Università della Magna Grecia (Germaneto,CZ): Pierosandro 
Tagliaferri, Angela Salvino. 
11. Ginecologia Ongologica, Centro di Ricerca e Formazione ad Alta Tecnologia nelle 
Scienze Biomediche, Uninversità Cattolica del Sacro Cuore (Campobasso): Gabriella 
Ferrandina, Aida Di Stefano, Francesca Risi. 
12. Oncologia Medica & Breast Unit, Ospedale “Senatore Antonio Perrino” (Brindisi): 
Saverio Cinieri, Enrica Mazzoni, Ermelinda Ferrara. 
13. Oncologia Medica, Istituto Nazionale Tumori Regina Elena (Roma): Antonella 
Savarese, Paola Malaguti, Agnese Provenziani. 
14. Oncologia Medica, Fondazione del Piemonte per l’Oncologia, IRCCS (Candiolo, TO): 
Giorgio Valabrega, Massimo Aglietta, Celeste Cagnazzo. 
15. Cattedra di Statistica Medica, Seconda Università di Napoli (Napoli): Ciro Gallo, 
Simona Signoriello, Giuseppe Signoriello, Paolo Chiodini. 
16. Unità Sperimentazioni Cliniche Istituto Nazionale per lo Studio e la Cura dei Tumori  
"Fondazione G.Pascale" IRCCS (Napoli): Francesco Perrone, Maria Carmela Piccirillo, 
Gennaro Daniele, Jane Bryce, Giuliana Canzanella, Federika Crudele, Manuela Florio, 
Giovanni De Matteis, Cristiana De Luca, Anna Gimigliano, Fiorella Romano, Antonia 
Del Giudice, Marilena Martino, Maria Teresa Ribecco, Alfonso Savio, Lucia 
Sparavigna. 
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